Gene · 9475
Papers3,801
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,801
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 2021-2022 Drug Updates in Hematologic Malignancies. | J Adv Pract Oncol | 2023 | 37197730 | PubTator, text mining | PubMed |
| Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities. | Front Oncol | 2023 | 37197432 | PubTator, text mining | PubMed |
| Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK. | J Ethnopharmacol | 2023 | 37196814 | PubTator, text mining | PubMed |
| Protein kinases: drug targets for immunological disorders. | Nat Rev Immunol | 2023 | 37188939 | PubTator, text mining | PubMed |
| Elucidating a fresh perspective on the interplay between exosomes and rheumatoid arthritis. | Front Cell Dev Biol | 2023 | 37187619 | PubTator, text mining | PubMed |
| Identification of Potential Biomarkers for Group I Pulmonary Hypertension Based on Machine Learning and Bioinformatics Analysis. | Int J Mol Sci | 2023 | 37175757 | PubTator, text mining | PubMed |
| Effects of Rho-Associated Kinase (Rock) Inhibitors (Alternative to Y-27632) on Primary Human Corneal Endothelial Cells. | Cells | 2023 | 37174707 | PubTator, text mining | PubMed |
| IL-22-Activated MUC13 Impacts on Colonic Barrier Function through JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK Signaling. | Cells | 2023 | 37174625 | PubTator, text mining | PubMed |
| Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. | Cell Mol Immunol | 2023 | 37165014 | PubTator, text mining | PubMed |
| Glucocorticoids promote lung metastasis of pancreatic cancer cells through enhancing cell adhesion, migration and invasion. | Endocr J | 2023 | 37164685 | PubTator, text mining | PubMed |
| Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis. | Bioorg Chem | 2023 | 37163811 | PubTator, text mining | PubMed |
| Transgenerational transmission of reproductive and metabolic dysfunction in the male progeny of polycystic ovary syndrome. | Cell Rep Med | 2023 | 37148878 | PubTator, text mining | PubMed |
| Cofilin activation in pancreatic acinar cells plays a pivotal convergent role for mediating CCK-stimulated enzyme secretion and growth. | Front Physiol | 2023 | 37138671 | PubTator, text mining | PubMed |
| BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. | Clin Transl Med | 2023 | 37132170 | PubTator, text mining | PubMed |
| Role of pyroptosis in the pathogenesis and treatment of diseases. | MedComm (2020) | 2023 | 37125240 | PubTator, text mining | PubMed |
| Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors. | Bioorg Med Chem Lett | 2023 | 37119973 | PubTator, text mining | PubMed |
| KDM4C silencing inhibits cell migration and enhances radiosensitivity by inducing CXCL2 transcription in hepatocellular carcinoma. | Cell Death Discov | 2023 | 37117173 | PubTator, text mining | PubMed |
| GPR35 antagonist CID-2745687 attenuates anchorage-independent cell growth by inhibiting YAP/TAZ activity in colorectal cancer cells. | Front Pharmacol | 2023 | 37113762 | PubTator, text mining | PubMed |
| Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches. | Pharmaceutics | 2023 | 37111734 | PubTator, text mining | PubMed |
| Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer's Disease. | Pharmaceuticals (Basel) | 2023 | 37111379 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9475/papers?page=25